| Tanya Hayden |
Tanya Hayden is currently the Chief Operating Officer at Acer Therapeutics, Inc. She previously worked as the Director of Operational Excellence at Lonza Group AG from 2018 to 2021 and as the Vice President of Manufacturing at Bend Research, Inc. from 2014 to 2018. Ms. Hayden completed her undergraduate degree at Gonzaga University. |
| John M. Klopp |
John M. Klopp is currently the Chief Technical Officer at Acer Therapeutics, Inc. Prior to this, he worked as the Senior Director-Manufacturing Management at Ultragenyx Pharmaceutical, Inc. from 2013 to 2018. Mr. Klopp received his undergraduate degree from The Pennsylvania State University and his graduate degree from the University of California, Berkeley. |
| Bernie Paul |
Bernie Paul is currently the Chief People Officer at Acer Therapeutics, Inc. He previously worked as the Vice President-Human Resources at Corixa Corp. from 1995 to 2006, at Emergent Product Development Seattle from 2006 to 2011, and at Pacific Bioscience Laboratories, Inc. from 2011 to 2017. Mr. Paul holds a graduate degree from the State University of New York at Buffalo and an undergraduate degree from Montana State University Billings. |
| Jefferson E. Davis |
Jefferson E. Davis founded Censa Pharmaceuticals, Inc. in 2019, where he worked as Vice President-Corporate Development from 2019 to 2020. Mr. Davis also founded Atacama Therapeutics, Inc., where he worked as Chief Business Officer. Mr. Davis also currently works at Commercial Bank of Texas, N.A., as Director and Acer Therapeutics, Inc., as Chief Business Officer from 2021. Mr. Davis also formerly worked at Archemix Corp., as Senior Director-Corporate Development, Extera Partners LLC, as Partner from 2011 to 2020, and Acer Therapeutics, Inc., as Chief Business Officer from 2013 to 2018. Mr. Davis received his Masters Business Admin degree from Duke University and undergraduate degree from North Carolina State University. |
| Luc Marengère |
Dr. Luc Marengère is Managing Partner at TVM Life Science Management, Inc. He is on the Board of Directors at CoLucid Pharmaceuticals, Inc., Albireo AB, Ixchelsis Ltd., Modulate Therapeutics, Inc. and PRCL Research Inc. Dr. Marengère was previously employed as Managing General Partner by VenGrowth Capital Partners, Inc., a Principal by Amgen, Inc., Co-President & Partner by CDP Capital Private Equity, an Investment Manager by Lumira Capital Corp., an Analyst by MedTech Partners, Inc., and a Principal by University Medical Discoveries, Inc. He also served on the board at Aegera Therapeutics, Inc., Argos Therapeutics, Inc., Cita Neuro Pharmaceuticals, Inc., Cytochroma, Inc., LymphoSign, Inc., Trillium Therapeutics, Inc. /Old/ and VisualSonics, Inc. He received his undergraduate degree from the University of Ottawa, a graduate degree from Queen's University and a doctorate degree from the University of Toronto. |
